Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2009Clinical Interventions in AgingOpen Access

Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension

View Full Paper
Ask AI
Bookmark
Share

Key result

Aliskiren and other renin-angiotensin-aldosterone system inhibitors are promising for managing hypertension and end-organ protection, though long-term mortality data are currently lacking.

Why the study?

Do RAAS inhibitors, including aliskiren, provide effective blood pressure control and end-organ protection in elderly patients with hypertension compared to older agents?

Population

Elderly patients with hypertension

Comparison

Aliskiren and other renin-angiotensin-aldosterone… vs Beta-blockers and thiazide diuretics

Design

Review

Authors

KAKarl Andersen

Discussion

Loading...

Member takes

Overview

May support RAAS inhibitor use in elderly hypertension; leaves open long-term mortality trials for aliskiren.

Structured PICO

Do RAAS inhibitors, including aliskiren, provide effective blood pressure control and end-organ protection in elderly patients with hypertension compared to older agents?

P
Population
Elderly patients with hypertension
I
Intervention
Aliskiren and other renin-angiotensin-aldosterone system (RAAS) inhibitors
C
Comparator
Beta-blockers and thiazide diuretics (historical comparison)
O
Outcome
Cardiovascular complications and end organ damage

RAAS inhibitors are established as safe and effective first-line treatments for hypertension, but long-term mortality data for direct renin inhibitors like aliskiren are still needed.

Limitations

  • Lack of data on the long-term effect of aliskiren on mortality
  • Safety of aliskiren is unexplored in certain patient groups

Cite This Study

Karl Andersen (2009) conducted a review in Hypertension. Aliskiren was evaluated. Aliskiren and other renin-angiotensin-aldosterone system inhibitors are promising for managing hypertension and end-organ protection, though long-term mortality data are currently lacking.

synapsesocial.com/papers/6a1c95d366d062ff2dc3fcc3https://doi.org/10.2147/cia.s3216
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension2007 · 58 citations
  2. 2Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan2006 · 214 citations
  3. 3Health Outcomes Associated With Antihypertensive Therapies Used as First-Line Agents<subtitle>A Systematic Review and Meta-analysis</subtitle>1997 · 878 citations
  4. 4Aliskiren, a Novel Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Placebo-Like Tolerability in Japanese Patients with Hypertension2006 · 85 citations
  5. 5Aliskiren, a Human Renin Inhibitor, Ameliorates Cardiac and Renal Damage in Double-Transgenic Rats2005 · 246 citations